Accéder au contenu
Merck

Chronic activation of a designer G(q)-coupled receptor improves β cell function.

The Journal of clinical investigation (2013-03-13)
Shalini Jain, Inigo Ruiz de Azua, Huiyan Lu, Morris F White, Jean-Marc Guettier, Jürgen Wess
RÉSUMÉ

Type 2 diabetes (T2D) has emerged as a major threat to human health in most parts of the world. Therapeutic strategies aimed at improving pancreatic β cell function are predicted to prove beneficial for the treatment of T2D. In the present study, we demonstrate that drug-mediated, chronic, and selective activation of β cell G(q) signaling greatly improve β cell function and glucose homeostasis in mice. These beneficial metabolic effects were accompanied by the enhanced expression of many genes critical for β cell function, maintenance, and differentiation. By employing a combination of in vivo and in vitro approaches, we identified a novel β cell pathway through which receptor-activated G(q) leads to the sequential activation of ERK1/2 and IRS2 signaling, thus triggering a series of events that greatly improve β cell function. Importantly, we found that chronic stimulation of a designer G(q)-coupled receptor selectively expressed in β cells prevented both streptozotocin-induced diabetes and the metabolic deficits associated with the consumption of a high-fat diet in mice. Since β cells are endowed with numerous receptors that mediate their cellular effects via activation of G(q)-type G proteins, our findings provide a rational basis for the development of novel antidiabetic drugs targeting this class of receptors.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Clozapine
Supelco
Clozapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Clozapine, European Pharmacopoeia (EP) Reference Standard
Clozapine for peak identification, European Pharmacopoeia (EP) Reference Standard